ADC Therapeutics (ADCT) Stock Price, News & Analysis

Company Overview

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Key Stats

• Today's Range: $2.12 to $2.21
• 50-Day Range: $1.89 to $3.48
• 52-Week Range: $1.18 to $6.04
• Volume: 98,185 shs
• Average Volume: 706,039 shs
• Market Capitalization: $207.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

ADC Therapeutics Stock Analysis - MarketRank™

ADC Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 435th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ADC Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ADC Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ADC Therapeutics are expected to grow in the coming year, from ($1.67) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ADC Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ADC Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.11% of the outstanding shares of ADC Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

ADC Therapeutics has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in ADC Therapeutics has recently decreased by 4.75%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADC Therapeutics does not currently pay a dividend.

Dividend Growth

ADC Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.11% of the outstanding shares of ADC Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

ADC Therapeutics has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in ADC Therapeutics has recently decreased by 4.75%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.61

News Sentiment

ADC Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for ADC Therapeutics this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

5 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, ADC Therapeutics insiders have bought 479.28% more of their company's stock than they have sold. Specifically, they have bought $304,000.00 in company stock and sold $52,479.00 in company stock.

Percentage Held by Insiders

Only 4.10% of the stock of ADC Therapeutics is held by insiders.

Percentage Held by Institutions

41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADCT Stock Analysis - Frequently Asked Questions

How have ADCT shares performed this year?

ADC Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, ADCT stock has increased by 28.3% and is now trading at $2.13.
View the best growth stocks for 2024 here.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.06. The company earned $18.46 million during the quarter, compared to analyst estimates of $18.76 million.

When did ADC Therapeutics IPO?

ADC Therapeutics (ADCT) raised $126 million in an initial public offering on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

Top institutional shareholders of ADC Therapeutics include Redmile Group LLC (16.21%), State Street Corp (1.14%), Geode Capital Management LLC (0.99%) and Sphera Funds Management LTD. (0.21%). Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby.
View institutional ownership trends.

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ADCT
• CUSIP: N/A
• CIK: 1771910
• Web: www.adctherapeutics.com
• Phone: 41-21-653-0200
• Fax: N/A
• Employees: 310
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +275.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-240,050,000.00
• Net Margins: -300.00%
• Pretax Margin: -233.27%
• Return on Equity: N/A
• Return on Assets: -61.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.92
• Quick Ratio: 4.68

Sales & Book Value

• Annual Sales: $70.72 million
• Price / Sales: 2.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.93) per share
• Price / Book: -1.10

Miscellaneous

• Outstanding Shares: 96,690,000
• Free Float: 92,726,000
• Market Cap: $205.95 million
• Optionable: Optionable
• Beta: 1.52